The answer so far
Kybella is a prescription injection containing deoxycholic acid, a substance that can break down fat cells at the injection site. In the United States it is approved for the appearance of moderate-to-severe fullness from fat under the chin in adults. It is not a peptide and is not a general weight-loss medicine.1
On this page
Why would someone ask about this injection?
Fullness under the chin can concern someone’s appearance, but it is not in itself evidence of poor health and there is no obligation to change it. Fullness can have more than one cause: the US label says providers should consider other possible explanations, such as enlarged glands. Kybella is designed for a defined cosmetic outcome in a defined location. It is different from an appetite medicine or an experimental peptide; compare the ideas in fat-dissolving injections versus weight-loss medicines.1
- Study258 people received deoxycholic acid and 258 placebo.
- One-grade improvement66.5% versus 22.2% improved on both patient and clinician scales.
- Two-grade improvement18.6% versus 3.0% reached this more demanding measure.
- Keep in mindAssessed 12 weeks after the last treatment; this is local appearance, not weight loss.
What is deoxycholic acid?
Deoxycholic acid is a bile acid, part of a family of substances involved in processing dietary fat. In the Kybella medicine it acts locally to break down fat cells. That local effect does not mean it increases whole-body fat burning or reduces weight. The ingredient is not a peptide. A product’s formulation, route and injection site matter; an ingredient name on a different vial does not make it the studied medicine.1
What did the trial find?
In REFINE-2, a company-sponsored, placebo-controlled trial, 258 adults received the medicine and 258 placebo injections. Twelve weeks after their last treatment, 66.5% versus 22.2% had at least a one-grade improvement on both clinician and patient under-chin rating scales. A larger, two-grade change occurred in 18.6% versus 3.0%. People’s experiences varied; these ratings concern a local appearance, not overall weight or a guarantee of satisfaction. The trial followed participants for up to 44 weeks.2
What are the common and serious risks?
In two pooled US trials, injection-site swelling was reported in 87% of people given Kybella versus 43% given placebo; pain in 70% versus 32%; and numbness in 66% versus 6%. Bruising was common in both groups, 72% versus 70%. These are trial figures, not a personal prediction.
The label also reports nerve injury around the jaw and difficulty swallowing. In the pooled trials, nerve injury was reported in 4% versus less than 1% and swallowing difficulty in 2% versus less than 1%. Nodules or masses, infection and tissue damage have been reported after approval; some lumps may persist. Voluntary reports cannot establish how often these occur. A qualified provider can discuss the exact risks, anatomy and alternatives.13
Is it approved for the stomach or elsewhere?
In the US, Kybella is not approved for fat outside the under-chin area, and the FDA recommends against such use. In September 2026 the agency added a warning after reviewing reports of serious reactions associated with use elsewhere, including nerve or muscle injury. Reports are signals for investigation, not a rate of harm. Approval and product names can differ in other countries; check the current local product information.31
What questions should I ask before a consultation?
Ask what the exact product is, what is causing the fullness, the result it was studied to change, possible alternatives and the qualifications of the person providing care. Mention relevant medicines and prior procedures, and ask how adverse effects will be handled. The US label says Kybella should be administered by a healthcare provider. It is not a product for self-injection.1
How does this differ from online “fat dissolvers”?
A different brand, mixture or seller claim does not inherit Kybella’s evidence or approval. The FDA has warned about reports of scars, infections and other injuries from unapproved injectable products in the US. Its warning is jurisdiction-specific: do not assume the same legal status elsewhere. See how local injections, peptides and appetite medicines differ.43
Sources, kept close.
Selected supporting sources; this is not a complete literature review.
- Kybella (deoxycholic acid) prescribing information, revised September 2026US Food and Drug Administration · Official product label
- ATX-101 for reduction of submental fat: A phase III randomized controlled trialJournal of the American Academy of Dermatology / PubMed · Randomised placebo-controlled trial
- FDA Approves Additional Information in Labeling for Kybella Warning of Adverse Reactions Associated with Unapproved UseUS Food and Drug Administration · Regulatory safety communication
- Using Fat-Dissolving Injections That Are Not FDA Approved Can Be HarmfulUS Food and Drug Administration · Consumer safety communication